Home | Multiple Myeloma Hub

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Steering Committee About Us Newsletter Contact

Visit:

Steering Committee About Us Newsletter Contact

Types Therapeutics Congresses Trials Expert Opinions

ASH 2020

Multiple Myeloma Types

Selinexor compared with the current standard of care in penta-treated, triple-class refractory patients with MM

Patients with multiple myeloma (MM) who relapse or become refractory to therapeutic agents tend to have a poor prognosis—often only a few...

Oct 27, 2020

| MM

TOURMALINE-MM2 trial: Ixazomib with Rd versus Rd in newly diagnosed patients with MM

Transplant ineligible patients who are diagnosed with multiple myeloma (MM) are a diverse group; some are fit while some are very frail, which means one treatment...

Oct 26, 2020

| COMy 2020

Second part of the phase III CASSIOPEIA study meets its primary endpoint

Positive topline results from the second part of the phase III CASSIOPEIA (NCT02541383) study were announced on October 21, 2020. The first part of the CASSIOPEIA study aimed to...

Oct 23, 2020

| MM

NICE recommends isatuximab in combination with pomalidomide and dexamethasone for the treatment of RRMM

On October 15, 2020, the National Institute for Health and Care Excellence (NICE) recommended the use of isatuximab (Isa) in combination with...

Oct 21, 2020

María-Victoria Mateos

" The MM Hub is the ideal platform for the latest news about myeloma. You will find information about the most recent data, and also personal experiences from experts managing myeloma patients in their clinical practice. "

Featured Expert Opinion

Which patients with smoldering multiple myeloma would you enrol in a clinical trial?

During the European School of Haematology (ESH) 5th Translational Research E-Conference on...

COMy 2020

TOURMALINE-MM2 trial: Ixazomib with Rd versus Rd in newly diagnosed patients with MM

Transplant ineligible patients who are diagnosed with multiple myeloma (MM) are a diverse group; some are fit while...

Oct 26, 2020

| COMy 2020

Why do we need to harmonize the use of MRD in MM?

During the 6th World Congress on Controversies in Multiple Myeloma (COMy) the Multiple Myeloma Hub spoke to Bruno Paiva, University of Navarra,...

Oct 19, 2020

| COMy 2020

Should all patients with MM receive maintenance therapy after transplantation?

During the 6th World Congress on Controversies in Multiple Myeloma (COMy) the Multiple Myeloma Hub spoke to Graham...

Oct 13, 2020

| COMy 2020

Should anti-CD38 antibodies be used in all patients as induction therapy prior to transplant?

During The 6th World Congress on Controversies in Multiple Myeloma (COMy), Francesca Gay and Mohamad Mohty...

Jul 16, 2020

| COMy 2020

EBMT 2020

Is there an optimal time to deploy immunotherapies in multiple myeloma?

During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub...

Oct 16, 2020

| EBMT 2020

New SLAMF7-targeted CAR T-cell therapy

During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub spoke to Hermann Einsele, University...

Sep 29, 2020

| EBMT 2020

At what point should allo-SCT (or auto-allo-SCT) be considered for patients with MM?

During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple...

Sep 25, 2020

| EBMT 2020

How can we predict responses to CAR T-cell therapies, such as bb2121?

During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub spoke...

Sep 14, 2020

| EBMT 2020

Chromosomal aberrations

How to use MRD status to treat high-risk multiple myeloma

This month, the Multiple Myeloma Hub is exploring the theme of high-risk multiple myeloma (MM). The first article on this subject dealt with...

Oct 10, 2020

| MM

KRd plus auto-SCT induces high-quality durable responses in NDMM

The results of a phase II trial (NCT01816971) that investigated the addition of autologous stem cell transplantation (auto-SCT) to KRd...

Sep 23, 2020

The clinical significance of chromosome 1 abnormalities in newly diagnosed multiple myeloma

After our recent overview of common cytogenetic abnormalities associated with a higher risk of relapse, we...

Sep 9, 2020

Is dara + VTd the best induction treatment for high-risk patients with newly diagnosed MM?

During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the...

Sep 3, 2020

| EBMT 2020

Most Viewed

Which patients with smoldering multiple myeloma would you enrol in a clinical trial?

Why do we not see curative CAR T-cell therapy in MM (compared to DLBCL and ALL)?

How to treat triple-class refractory MM?

How can we predict responses to CAR T-cell therapies, such as bb2121?

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Selinexor compared with the current standard of care in penta-treated, triple-class refractory patients with MM

Oct 27, 2020

| MM

Oct 26, 2020

| COMy 2020

Oct 23, 2020

| MM

Oct 21, 2020

| MM

María-Victoria Mateos

COMy 2020

Oct 26, 2020

| COMy 2020

Oct 19, 2020

| COMy 2020

Oct 13, 2020

| COMy 2020

Jul 16, 2020

| COMy 2020

EBMT 2020

Oct 16, 2020

| EBMT 2020

Sep 29, 2020

| EBMT 2020

Sep 25, 2020

| EBMT 2020

Sep 14, 2020

| EBMT 2020

Most Read

Chromosomal aberrations

Oct 10, 2020

| MM

Sep 23, 2020

Sep 9, 2020

Sep 3, 2020

| EBMT 2020

Most Viewed